中国药物警戒 ›› 2011, Vol. 8 ›› Issue (12): 729-730.

• 管理及工作研究 • 上一篇    下一篇

喜炎平注射液上市后安全性风险分析

杨乐   

  1. 国家食品药品监督管理局药品评价中心,北京 100045
  • 收稿日期:2011-06-29 出版日期:2011-12-10 发布日期:2015-07-30
  • 作者简介:杨乐,男,主管药师,药品不良反应监测与评价。

Post-marketing Safty and Risk Analysis of Xiyanping Injection

YANG Le   

  1. Center for Drug Reevaluation, SFDA, Beijing 100045, China
  • Received:2011-06-29 Online:2011-12-10 Published:2015-07-30

PDF (PC)

281

摘要： 通过对喜炎平注射液安全性相关的国内文献报道、上市后的安全性研究状况进行分析,评价喜炎平注射液上市后的安全性情况及风险特点,提出符合药品本身特点的风险控制措施。为安全、合理使用该药提供建议。

关键词: 喜炎平注射液, 安全性风险, 风险控制, 措施

Abstract: By reviewing the relevant references and reports of the adverse drug reaction cases of Xiyanping in China, and analyzing the post marketing safety studies, the safety and risks in post-marketing period of Xiyanping is reevaluated in this article. The author puts forward risk management measures according to the characteristics of medicine. Suggestions are proposed for a safe and rational use of this medicine.

Key words: Xiyanping injection, safety and risk in post-marketing, risk control, measure

中图分类号: